Apogee Therapeutics, Inc. (APGE)

Market Cap	2.71B
Revenue (ttm)	n/a
Net Income (ttm)	-146.66M
Shares Out	56.90M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	566,386
Open	46.48
Previous Close	47.02
Day's Range	45.51 - 48.42
52-Week Range	25.85 - 72.29
Beta	n/a
Analysts	Strong Buy
Price Target	75.40 (+58.04%)
Earnings Date	Nov 12, 2024

About APGE

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended ha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: APGE
• Website: https://www.apogeetherapeutics.com

Analyst Forecast

According to 6 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price forecast is $75.4, which is an increase of 58.04% from the latest price.

Price Target

$75.4

(58.04% upside)

Analyst Consensus: Strong Buy